NESS ZIONA, Israel, April 11, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) reported today the first participant enrollment in the United States in a Phase 2 clinical trial of the company's universal flu vaccine candidate, M-001. The trial is sponsored by the US...